Fig. 6: Ruxo suppresses IFNγR1^KO but not scrambled control melanomas.

a Growth of scrambled control melanomas in B6 mice treated with vehicle (UnTx, n = 5) or with Ruxo (90 mg/kg by oral gavage twice daily) (n = 5) for 10 days. b–e B6 mice bearing IFNγR1^KO melanoma were treated as in a. b Tumor growth: n = 8 per group; ****p = 0.0002 by two-way ANOVA with Šídák’s multiple comparisons test. c Tumor weights at euthanization (n = 8 per group; *p = 0.0422). Isolated TILs from these mice were analyzed for frequency of FoxP3⁺ T_reg (d) (n = 8 per group; ****p = 0.0003) and cytokine production of TNF, IFN-γ, Perforin, and IL-2 in CD4⁺ TILs (e) (n = 5 per group; *p = 0.0233 for TNF; *p = 0.011 for IFN-γ; *p = 0.0311 for Perforin; *p = 0.0319 for IL-2) after a brief stimulation with PMA and ionomycin. f, g Isolated TILs were cultured with 100 U/mL IL-2, ±1 μM Ruxo, for 3 days, to analyze FoxP3⁺ T_reg (f) (n = 3 per group; *p = 0.0346; ****p = 0.00009) and IFN-γ/TNF production (g) (n = 3 per group; *p = 0.0488) in CD4⁺ TILs after a brief stimulation with PMA and ionomycin by flow cytometry (FACS strategy 3). A two-sided Student’s t-test was used in c–g for statistical analyses. The scatter plots and line graphs depict means ± SEM. Source data are provided in the Source Data file.